Catalog entry human-reviewed · each study below is labeled with how it was published · How we review →
Auto-discovered from 1 recent study; not yet curated.
4 studies2 human1 animal1 review/other
Tracking 4 published studies of Trastuzumab Deruxtecan: 2 in humans, 1 in animals, 1 reviews/other.
Reported direction across studies: 4 positive.
These counts summarize what the studies reported; they are not a measure of whether Trastuzumab Deruxtecan works.
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 10
BMC cancer · Dec 2024 · retrospective cohort
Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.
Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more
Key findings
- 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
- Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
- Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
- HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
- Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
- Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
- Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
- Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
- Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Animal studyReported positivePreclinical onlyTier 2 · animal
Molecular cancer therapeutics · Dec 2023
The study tested trastuzumab deruxtecan (T-DXd) against primary uterine serous carcinoma cell lines and patient-derived xenografts. T-DXd suppressed growth, increased apoptosis, and induced antibody-dependent cellular cytotoxicity in HER2-overexpressing (3+) models, showed bystander killing in mixed HER2-high/low cultures, and reduced tumor growth and prolonged survival in HER2 3+ PDX models with minimal toxicity. Little activity was seen against low HER2-expressing cell lines.
Key findings
- T-DXd induced cell growth suppression in HER2-overexpressing cell lines in vitro.
- T-DXd increased early and late apoptosis as assessed by annexin and propidium iodide staining.
- T-DXd induced significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes, similarly to trastuzumab.
- Negligible activity was detected against USC cell lines with low HER2 expression.
- T-DXd demonstrated significant bystander killing against USC tumors with low/negligible HER2 when such cells were admixed with HER2 3+ tumor cells in vitro.
- T-DXd showed tumor growth suppression in in vivo USC PDX models that overexpress HER2 at 3+ levels, prolonging survival when compared with controls, with minimal toxicity.
Limitations: Preclinical study only (in vitro cell lines and in vivo PDX models); no human data reported.; Abstract provides no details on sample sizes, doses, or statistical measures.; Activity was largely limited to HER2 3+ models; negligible activity in low HER2 expression lines.; Bystander killing was demonstrated in vitro with admixed cells; relevance in vivo is not shown in the abstract.; Resistance to trastuzumab was discussed but not directly modeled or tested in this study (no explicit trastuzumab-resistant models described)..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
Gynecologic oncology reports · Nov 2023 · case report
This case report describes a single patient with recurrent ovarian carcinosarcoma whose tumor showed low HER2 expression (IHC 1+ and negative FISH) and who received trastuzumab deruxtecan. The patient achieved a durable partial response. The authors suggest this could represent a possible treatment option for OCS patients with HER2 expression. The evidence is limited to a single case.
Key findings
- A patient with ovarian carcinosarcoma and HER2 IHC 1+ (FISH negative) was treated with trastuzumab deruxtecan.
- The patient achieved a durable partial response.
- Authors suggest trastuzumab deruxtecan may be a possible option for OCS patients with HER2 expression.
Limitations: Single-patient case report (n=1), limiting generalizability.; No control or comparator group.; No dose, treatment schedule, duration of response, or detailed safety data reported in the abstract.; Cannot establish efficacy or safety from a single case..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveModerate evidenceTier 4 · clinicaln = 32
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · May 2023 · single-arm phase II trial
This phase II study tested trastuzumab deruxtecan in people with recurrent uterine carcinosarcoma whose tumors expressed HER2. The study found tumor responses in both the HER2-high and HER2-low groups, and the median progression-free survival and overall survival were reported for each group. Side effects were common, including some serious adverse events and pneumonitis/interstitial lung disease, but the authors said they were generally manageable with monitoring.
Reported effects: ORR by central review 54.5% [32.2–75.6], n=22 · ORR by central review 70% [34.8–93.3], n=10 · +6 more
Key findings
- Central-review ORR was 54.5% in the HER2-high group and 70.0% in the HER2-low group.
- Investigator-assessed ORR was 68.2% in the HER2-high group and 60.0% in the HER2-low group.
- Median PFS was 6.2 months in the HER2-high group and 6.7 months in the HER2-low group.
- Median OS was 13.3 months in the HER2-high group and not reached in the HER2-low group.
- Grade ≥3 adverse events occurred in 61% of patients.
- Pneumonitis/interstitial lung disease occurred in 24% at grade 1-2 and 3% at grade 3.
Limitations: Single-arm study with no control group; Small sample size; Short/unclear follow-up for survival outcomes; Subgroup analyses were exploratory; Safety and efficacy were assessed in a selected HER2-expressing recurrent population.
This study evaluated an anticancer agent in patients with HER2-expressing uterine carcinosarcoma.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Cancers where Trastuzumab Deruxtecan reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Human evidence
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (2)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (2)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (2)
Endometrial neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Ovarian neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Cervical neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Evidence at a glance: Trastuzumab Deruxtecan by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.